Abstract
In immune responses several cell types have to cooperate. Within the LYMPHOID ORGANS, such as lymph nodes, spleen or PEYER’S PATCHES, the cells of the IMMUNE SYSTEM interact in a dynamic fashion. At all times some cells, especially T LYMPHOCYTES, leave a lymphoid organ (such as a lymph node), circulate through the body and enter another lymphoid organ in search of a fitting antigen. As a consequence, the communication between the cells of the immune SYSTEM – LYMPHOCYTES, monocytic cells and GRANULOCYTES – depends on secreted diffusible mediators, the most important of which are the cytokines.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Vilcek J (2003) The cytokines: an overview. In: AW Thomson, M Lotze (eds): The Cytokine Handbook, 4th edn. Academic Press, London, 3–18
Leonard WJ (2008) Type I cytokines and interferons and their receptors. In: WE Paul (ed): Fundamental Immunology, 6th edn. Wolters Kluwer/Lippincott Williams and Wilkins, Philadelphia, 706–749
Dinarello CA (2008) Interleukin-1 family of ligands and their receptors. In: WE Paul (ed): Fundamental Immunology, 6th edn. Wolters Kluwer/Lippincott Williams and Wilkins, Philadelphia, 750–775
Wang X, Lupardus P, LaPorte SL Garcia KC (2009) Struc- tural biology of shared cytokine receptors. Annu Rev Immunol 27: 29–60
Wickrema A, Klee B (eds) (2009) Molecular Basis of Hematopoesis. Springer, Heidelberg
Smith TJ, Khatcheressian J, Lyman GH et al (2006) Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24: 3187–3205
Elliott SG, Foote MA, Molineux G (eds) (2009) Erythropoietins, Erythropoietic Factors and Erythropoiesis; Milestones in Drug Therapy, 2nd edn. Birkhauser, Basel
Kuter DJ (2009) Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med 60: 193–206
Rothenberg EV (2007) Cell lineage regulators in B and T cell development. Nat Immunol 8: 441–444
Stavnezer J, Guikema JEJ, Schrader CE (2008) Mechanism and regulation of class switch recombination. Annu Rev Immunol 26: 261–292
Smith-Garvin JE, Koretzky GA, Jordan MA (2009) T cell activation. Annu Rev Immunol 27: 591–619
Malek TR (2008) The biology of interleukin 2. Annu Rev Immunol 26: 453–479
Commins S, Steinke JW, Borish L (2008) The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL24, IL-26, IL 28, IL-29. J Allergy Clin Immunol 121: 1108–1111
Dong C (2008) Regulation and proinflammatory function of interleukin-17 family cytokines. Immunol Rev 226: 80–86
Ettinger R, Kuchen S, Lipsky PE (2008) The role of IL-21 in regulating B-cell function in health and disease. Immunol Rev 223: 60–86
Langrish CL, McKenzie BS, Wilson NJ de Waal Malefyt R, Kasteleine RA, Cua DJ (2004) IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 202: 96–105
Barlow JL, McKenzie AN (2009) IL-25: a key requirement for the regulation of type-2 immunity. Biofactors 35: 178–182
Yoshida H, Nakaya M, Miyazaki Y (2009) Interleukin-27: a double edged sword for offense and defense. J Leukoc Biol 86: 1295–1303
Zhang Q, Putheti P, Zhou Q, Liu Q, Gao W et al (2008) Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev 19: 347–356
Dinarello CA, Kim SH (2006) IL-32, a novel cytokinewith a possible role in disease. Ann Rheum Dis 65, supp l3: iii 61–64
Smith DE (2010) IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Immunol 40: 200–208
Garceau V, Smith J, Paton IR, Davey M, Fares MA, Sester DP et al (2010) Pivotal advance: avian colony-stimulationg factor 1 (CSF 1), interleukin-34, and CSF-1 receptor genes and gene products. J Leukoc Biol 87: 753–764
Collison LW, Vignali DA (2008) Interleukin-35: odd one out or part of the family? Immunol Rev 226: 248–262
D’Acquisto F, Maione F, Pederzoli-Ribeil M (2010) From IL-15 to IL-33: the never ending list of new players in inflammation. Is it time to forget the humble aspirin and move ahead? Biochem Pharmacol 79: 525–534
Dale DC, Boxer L, Liles WC (2008) The phagocytes: neutrophils and monocytes. Blood 112: 935–945
Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454: 428–435
Nathan C (2002) Points of control in inflammation. Nature 420: 846–852
Sadler AJ, Williams BR (2008) Interferon-inducible antiviral effectors. Nat Rev Immunol 8: 559–568
Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR (2007) Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6: 975–990
Ware CF (2008) TNF-related cytokines in inflammation. In: WE Paul (ed): Fundamental Immunology, 6th edn. Wolters Kluwer/Lippincott Williams and Wilkins, Philadelphia, 776–803
Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27: 519–550
Ding C, Ciccutini F, Li J, Jones G (2009) Targeting IL-6 in the treatment of inflammatory and autoimmune diseases. Expert Opin Investig Drugs 18: 1457–1466
Bermel R, Weinstock-Guttman B, Bourdette D, Foulds P, You X, Rudick R et al (2010) Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. Mult Scler 16: 588–596
Goldman JM (2009) Treatment strategies for CML. Best Pract Res Clin Haematol 22 : 303–13
Chavez AR, Buchser W, Basse PH, Liang X, Appleman LJ, Maranchie JK et al (2009) Pharmacologic administration of interleukin-2. Ann NY Acad Sci 1182: 14–27 t
de Vries MR, ten Hagen TL, Marinelli AW, Eggermont AM (2003) Tumor necrosis factor and isolated hepatic perfusion: from preclinic tumor models to clinical studies. Anticancer Res 23: 1811–1823
Kircheis R, Ostermann E, Wolschek MF, Lichtenberger C, Magin-Lachmann C, Wightman L et al (2002) Tumortargeted gene delivery of tumor necrosos factor-alpha induces tumor necrosis and tumor regression without systemic toxicity. Cancer Gene Ther 9: 673–680
Griffin JD (2001) Hematopoietic growth factors. In: VT DeVita, S Hellman, SA Rosenberg (eds): Cancer Principles and Practice of Oncology. Lippincott/Williams and Wilkins, Philadelphia, 2798–2813
Fischer M, Goldschmitt J, Peschel C, Brakenhoff, Kallen KJ, Wollmer A et al (1997) A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol 15: 142–145
Mosmann TR, Sal S (1996) The expanding universe of T-subsets: Th1, Th2 and more. Immunol Today 17: 138–146
Fietta P, Delsante G (2009) The effector T helper tiade. Riv Biol 102: 61–74
Betteli E, Korn T, Oukka M, Kuchroo VK (2008) Induction and effector functions of TH17 cells. Nature 453: 1052–1057
Bluestone JA, Abbas AK (2003) Natural versus adaptive regulatory T cells. Nat Rev Immunol 3: 253–257
Vignale DAA, Collison LW, Workman CJ (2008) How regulatory T cells work. Nat Rev Immunol 8: 523–531
Sallusto F, Baggiolini M (2008) Chemokines and leukocyte traffic. Nat Immunol 9: 949–952
Bromley SK, Mempel TR, Luster AD (2008) Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 9: 970–980
Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4: 540–550
Wells TNC, Power CA, Shaw FP, Proudfoot AEI (2006) Chemokine blockers-therapeutics in the making? Trends Pharmacol Sci 27: 1–17
Mackay CR (2008) Moving targets: cell migration inhibitors as new anti-inflammatory therapies. Nat Immunol 9: 988–998
Mantovani A, Dinarello CA, Ghezzi P (2000) Pharmacology of cytokines. Oxford University Press, Oxford
Giliberto G, Savino R (2001) Cytokine Inhibitors. Marcel Dekker, New York
Feldmann M (2009) Translating molecular insights in autoimmunity into effective therapy. Annu Rev Immunol 27: 1–27
Taylor PC, Feldmann M (2009) Anti-TNF biologic agents: still the therapy of choice in rheumatoid arthritis. Nat Rev Rheumatol 5: 578–582
Dinarello CA (2009) Inflammation in human disease: anticytokine therapy. Biol Blood Marrow Transplant 15 (Suppl): 134–136
Daridon C, Burmester GR, Dorner T (2009) Anticytokine therapy impacting on B cells in autoimmune diseases. Curr Opin Rheumatol 21: 205–210
Liberman AC, Druker J, Perone MJ, Arzt E (2007) Glucocorticoids in the regulation of transcription factors that control cytokine synthesis. Cytokine Growth Factor Rev 18: 45–56
Braat H, Peppelenbosch MP, Hommes DW (2003) Interleukin-10 based therapy for inflammatory bowel disease. Expert Opin Biol Ther 3: 725–731
O’Neill LA (2006) Targeting signal transduction as a strategy to treat inflammatory diseases. Nat Rev Drug Discov 5: 549–563
Gaestel M, Kotlyarov A, Kracht M (2009) Targeting innate immunity protein kinase signalling in inflammation. Nat Rev Drug Discov 8: 480–4991
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Birkhäuser Basel
About this chapter
Cite this chapter
Resch, K., Martin, M.U. (2011). A5 Cytokines. In: Nijkamp, F., Parnham, M. (eds) Principles of Immunopharmacology. Birkhäuser Basel. https://doi.org/10.1007/978-3-0346-0136-8_5
Download citation
DOI: https://doi.org/10.1007/978-3-0346-0136-8_5
Published:
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-0346-0135-1
Online ISBN: 978-3-0346-0136-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)